RxDoctor Payments Data

Robert Murphy

North Little Rock, ARNPI 1356381982

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,948 of the $3,512 with a category attached, or 83.9%. 16 manufacturers reported payments, led by AbbVie at 32.6% of the total.

$3,512in general payments, 2019–2025

Across 196 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Braintree Laboratories, Inc.$512
  • Johnson & Johnson$476
  • Pfizer$254
  • Takeda Pharmaceuticals U.S.A., Inc.$243
  • Gilead$177
  • plus $703 from 10 others
$792,064in research payments, 2019–2025

Across 171 payments — averaging $4631.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$187K
  • AbbVie$185K
  • Gilead$178K
  • Braintree Laboratories, Inc.$102K
  • Shire North American Group Inc$83K
  • Ironwood Pharmaceuticals, Inc$40K
  • plus $16K from 1 others

What the payments were for

  • Food & beverage$2,94884%
  • Education$1003%
  • Gifts$46413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pantoprazole Sodium19$271

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →